NasdaqGM:PTGXBiotechs
Protagonist Therapeutics (PTGX) Stock Looks Stretched As A Price Target Boost Lands
Protagonist Therapeutics has delivered a very large 3 year return, yet its current valuation screens as expensive on market multiples and only mixed on broader checks, which raises questions about how much optimism is already in the share price.
Over the past 3 years, Protagonist Therapeutics has returned roughly 7x, which puts extra focus on whether recent gains can be supported by fundamentals over time.
Recent enthusiasm around the company, including a higher price target from Barclays,...